Medical devices — Application of risk management to medical devices

ISO 14971:2019, 'Medical devices — Application of risk management to medical devices,' is the international standard that outlines a systematic process for manufacturers to manage risks associated with medical devices. It is a process-based standard applicable throughout the entire product lifecycle, from initial concept to decommissioning. The core framework requires manufacturers to establish a risk management plan, identify hazards, estimate and evaluate associated risks, implement and verify risk controls, and assess the acceptability of any residual risks. It also mandates the active collection and review of production and post-production information to update risk assessments. Compliance with ISO 14971 is a regulatory requirement in major markets, including the European Union under the Medical Device Regulation (MDR, (EU) 2017/745) and the United States, where it is a consensus standard recognized by the FDA. It works in conjunction with ISO 13485 for quality management systems, forming the foundation of medical device safety and compliance.

Applying ISO 14971 involves a structured, documented process. Step 1: Planning. A cross-functional team establishes a Risk Management Plan defining the scope, activities, and criteria for risk acceptability for a specific device, as required by Clause 4. All activities are documented in a Risk Management File (RMF). Step 2: Risk Analysis and Evaluation. Following Clause 5, the team identifies known and foreseeable hazards using tools like Failure Mode and Effects Analysis (FMEA). They then estimate the severity and probability of occurrence for each harm, evaluating the risk against the predefined acceptability criteria. Step 3: Risk Control and Verification. For unacceptable risks, the team implements control measures per Clause 6, prioritizing inherent safety by design. The effectiveness of each control must be verified. For instance, a global infusion pump manufacturer used this process to identify a risk of over-infusion, implementing a software-based dose error reduction system as a control. This led to a 98% audit success rate and a 50% reduction in use-error-related complaints.

Taiwan enterprises, particularly small and medium-sized ones (SMEs), face several key challenges with ISO 14971. 1. Limited Resources and Expertise: Many SMEs lack dedicated risk management professionals and view the process as a documentation burden rather than an integral part of R&D. Solution: Develop modular risk management templates and provide practical, role-based training to embed risk management into existing engineering and quality roles. 2. Difficulty in Post-Market Surveillance (PMS) Data Integration: Data from complaints, service reports, and vigilance systems are often siloed, hindering the systematic feedback loop required by Clause 9. Solution: Implement an electronic Quality Management System (eQMS) to centralize PMS data, enabling trend analysis and proactive risk updates. 3. Overly Subjective Risk Assessments: Risk evaluations often rely on subjective judgment for probability and severity, which is frequently challenged by auditors. Solution: Establish an internal database of historical product data and leverage external sources like clinical literature to provide objective evidence for risk estimations.

Winners Consulting specializes in ISO 14971 for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact